Boehringer Ingelheim reports positive data from Viramune trial

Boehringer Ingelheim has published new clinical data which supports the efficacy of a new indication of its HIV drug Viramune.

The pharmaceutical company trialled a once-daily nevirapine extended release 400mg QD formulation of Viramune among HIV patients for 48 weeks as part of the new VErxVE study.

It was found that the new formulation demonstrated non-inferior performance to the currently-used twice-daily immediate release 200mg BID version of the drug, with consistent performance regardless of gender, ethnicity and baseline viral load.

Professor Klaus Dugi, corporate senior vice-president of medicine at Boehringer Ingelheim, stated that the results underline the efficacy of Viramune as an antiretroviral therapy.

He added: “We are confident that the extended release formulation, once approved, will enable HIV patients and their physicians to choose an effective, tolerable and durable treatment option with a favourable lipid profile.”

Last month, the company published new clinical trial data for the diabetes drug linagliptin, illustrating its effectiveness as both a monotherapy and combination treatment.